Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Froot Loops have sparked curiosity for years, leading to a popular conspiracy that questions whether each colourful loop actually has a different flavour. This video takes a closer look at where that ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

According to @godofprompt, recursive prompting is an AI technique where system outputs are fed back in as inputs to refine solutions through multiple iterations (source: @godofprompt, Dec 16, 2025).

Here’s how pinning a utopian vision for AI on LLMs kicked off the hype cycle that’s causing fears of a bubble today. Each time you’ve heard a borderline outlandish idea of what AI will be capable of, ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect of the process, including human developers using the tools to improve ...

Abstract: We revisit the concept of constraint embedding as a means for dealing with kinematic loop constraints during dynamics computations for rigid-body systems. Specifically, we consider the local ...

Marissa Sulek joined CBS News Chicago in January 2025. Before Chicago, Marissa was a general assignment reporter in Nashville at WSMV, where she was nominated for Mid-South Emmy Awards for her ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...